News and Events

Topical formulation of TTHX1114 has potential to accelerate the healing of epithelial defects – a leading cause of blindness worldwide SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced the

Chicago – September 29, 2022 – Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). TTHX1114, a proprietary

San Diego, CA, December 1, 2021 – Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A

Indianapolis, IN – March 10, 2021 – Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in conjunction with a surgical procedure that

Study evaluating engineered FGF-1’s (TTHX114) potential in patients undergoing Descemet Stripping Only (DSO or DWEK) procedures San Diego, CA – February 9, 2021 – Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast

San Diego, CA – November 12, 2020 – Trefoil Therapeutics, which is developing first-in-class regenerative treatments for corneal diseases, announced today it has received the ‘People’s Choice’ award at the inaugural Eyecelerator virtual conference.  The company’s lead product, an engineered

Trefoil provided an update on the company and its clinical program for TTHX1114 at the inaugural Eyecelerator 2020 virtual conference on November 6. TTHX1114 is the company’s first-in-class, engineered fibroblast growth factor 1 (FGF-1), for the regenerative treatment of corneal diseases. 

San Diego, CA – November 2, 2020 – Trefoil Therapeutics announced today it will provide an update on the company and its clinical program for TTHX1114 at the upcoming Eyecelerator virtual conference.  TTHX1114 is the company’s first-in-class, engineered fibroblast growth

Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells  San Diego, CA – August 19, 2020 – Trefoil Therapeutics today announced it has initiated the first clinical trial of its engineered Fibroblast

Trefoil Therapeutics presents the proliferation of human corneal endothelia in organ culture stimulated by engineered human fibroblast growth factor 1 (FGF1) derivative TTHX1114